JP2008525468A - ポストコンディショニング臓器保護作用を増強する治療補助薬 - Google Patents
ポストコンディショニング臓器保護作用を増強する治療補助薬 Download PDFInfo
- Publication number
- JP2008525468A JP2008525468A JP2007548436A JP2007548436A JP2008525468A JP 2008525468 A JP2008525468 A JP 2008525468A JP 2007548436 A JP2007548436 A JP 2007548436A JP 2007548436 A JP2007548436 A JP 2007548436A JP 2008525468 A JP2008525468 A JP 2008525468A
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- inhibitor
- organ
- perfusion
- reperfusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000056 organ Anatomy 0.000 title claims abstract description 119
- 230000010411 postconditioning Effects 0.000 title abstract description 88
- 238000011282 treatment Methods 0.000 title description 8
- 230000004224 protection Effects 0.000 title description 4
- 239000002671 adjuvant Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 96
- 230000010410 reperfusion Effects 0.000 claims abstract description 95
- 230000006378 damage Effects 0.000 claims abstract description 55
- 210000002216 heart Anatomy 0.000 claims abstract description 45
- 239000003223 protective agent Substances 0.000 claims abstract description 35
- 230000002669 organ and tissue protective effect Effects 0.000 claims abstract description 30
- 230000000747 cardiac effect Effects 0.000 claims abstract description 13
- 210000001519 tissue Anatomy 0.000 claims description 105
- 230000010412 perfusion Effects 0.000 claims description 78
- 230000000302 ischemic effect Effects 0.000 claims description 60
- 208000027418 Wounds and injury Diseases 0.000 claims description 43
- 208000014674 injury Diseases 0.000 claims description 42
- 210000004351 coronary vessel Anatomy 0.000 claims description 40
- 239000003112 inhibitor Substances 0.000 claims description 28
- IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical group CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 claims description 25
- 229950008393 cariporide Drugs 0.000 claims description 25
- 230000009467 reduction Effects 0.000 claims description 21
- 210000004204 blood vessel Anatomy 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 16
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 claims description 9
- 108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 238000007906 compression Methods 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 5
- 108091006146 Channels Proteins 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 5
- 239000000158 apoptosis inhibitor Substances 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 239000000480 calcium channel blocker Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000002438 mitochondrial effect Effects 0.000 claims description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 5
- 230000037050 permeability transition Effects 0.000 claims description 5
- FCTRVTQZOUKUIV-MCDZGGTQSA-M potassium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O FCTRVTQZOUKUIV-MCDZGGTQSA-M 0.000 claims description 5
- 229940125794 sodium channel blocker Drugs 0.000 claims description 5
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 5
- 210000001508 eye Anatomy 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 210000002027 skeletal muscle Anatomy 0.000 claims description 3
- 229940124170 Sodium/hydrogen exchange inhibitor Drugs 0.000 claims 8
- 229940123271 Endothelin 1 antagonist Drugs 0.000 claims 4
- 230000003444 anaesthetic effect Effects 0.000 claims 4
- 230000019491 signal transduction Effects 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 abstract description 49
- 230000000694 effects Effects 0.000 abstract description 22
- 208000010125 myocardial infarction Diseases 0.000 abstract description 20
- 230000017531 blood circulation Effects 0.000 description 30
- 210000004165 myocardium Anatomy 0.000 description 28
- 230000002829 reductive effect Effects 0.000 description 26
- 206010061216 Infarction Diseases 0.000 description 25
- 230000007574 infarction Effects 0.000 description 25
- 230000010413 ischemic postconditioning Effects 0.000 description 21
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 16
- 206010063837 Reperfusion injury Diseases 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- 210000000440 neutrophil Anatomy 0.000 description 13
- 102000004420 Creatine Kinase Human genes 0.000 description 12
- 108010042126 Creatine kinase Proteins 0.000 description 12
- 230000002530 ischemic preconditioning effect Effects 0.000 description 12
- 102000003896 Myeloperoxidases Human genes 0.000 description 11
- 108090000235 Myeloperoxidases Proteins 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 10
- 210000003038 endothelium Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 206010028851 Necrosis Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000017074 necrotic cell death Effects 0.000 description 9
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 8
- 229960005305 adenosine Drugs 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 230000036770 blood supply Effects 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000001778 Coronary Occlusion Diseases 0.000 description 5
- 206010011086 Coronary artery occlusion Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 230000008753 endothelial function Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000037906 ischaemic injury Diseases 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 4
- 206010064966 Myocardial oedema Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 4
- 210000002464 muscle smooth vascular Anatomy 0.000 description 4
- 238000013146 percutaneous coronary intervention Methods 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- LXJSJIXZOAMHTG-UHFFFAOYSA-N 4-(1,3-dimethyl-2,6-dioxo-7h-purin-8-yl)benzenesulfonic acid Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1=CC=C(S(O)(=O)=O)C=C1 LXJSJIXZOAMHTG-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 230000005961 cardioprotection Effects 0.000 description 3
- 238000007887 coronary angioplasty Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical group [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010038563 Reocclusion Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000008828 contractile function Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 208000012866 low blood pressure Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229960002460 nitroprusside Drugs 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000002883 vasorelaxation effect Effects 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 229940127600 A2A receptor antagonist Drugs 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010053261 Coronary artery reocclusion Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 description 1
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 1
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000014458 Protein Kinase C-epsilon Human genes 0.000 description 1
- 108010078137 Protein Kinase C-epsilon Proteins 0.000 description 1
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 229940100084 cardioplegia solution Drugs 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229950011365 eniporide Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- UADMBZFZZOBWBB-UHFFFAOYSA-N n-(diaminomethylidene)-2-methyl-5-methylsulfonyl-4-pyrrol-1-ylbenzamide Chemical group C1=C(C(=O)N=C(N)N)C(C)=CC(N2C=CC=C2)=C1S(C)(=O)=O UADMBZFZZOBWBB-UHFFFAOYSA-N 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- -1 sachets Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63846104P | 2004-12-22 | 2004-12-22 | |
| PCT/US2005/046417 WO2006069170A2 (en) | 2004-12-22 | 2005-12-20 | Therapeutic adjuncts to enhance the organ protective effects of postconditioning |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008525468A true JP2008525468A (ja) | 2008-07-17 |
| JP2008525468A5 JP2008525468A5 (https=) | 2009-01-29 |
Family
ID=36602296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548436A Withdrawn JP2008525468A (ja) | 2004-12-22 | 2005-12-20 | ポストコンディショニング臓器保護作用を増強する治療補助薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080097385A1 (https=) |
| EP (1) | EP1827298A4 (https=) |
| JP (1) | JP2008525468A (https=) |
| AU (1) | AU2005319144A1 (https=) |
| CA (1) | CA2592142A1 (https=) |
| WO (1) | WO2006069170A2 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012210361A (ja) * | 2011-03-31 | 2012-11-01 | Terumo Corp | 肢部圧迫装置 |
| JP2013510832A (ja) * | 2009-11-16 | 2013-03-28 | アンスティテュ ナシオナル ドゥ ラ ルシェルシュ アグロノミック | Ａ型インフルエンザウイルス感染症の治療または予防用のｐａｒ−１アンタゴニスト |
| JP2013523240A (ja) * | 2010-03-31 | 2013-06-17 | ザ・ホスピタル・フォー・シック・チルドレン | 心筋梗塞後の結果を改善するための遠隔虚血コンディショニングの使用 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ514515A (en) | 1999-03-23 | 2003-11-28 | Global Cardiac Solutions Pty L | Organ arrest, protection and preservation using a potassium channel operator and/or adenosine receptor and a local anaesthetic |
| AU2002336650B2 (en) | 2001-10-25 | 2008-06-05 | Emory University | Catheter for modified perfusion |
| EP3064242A1 (en) | 2003-04-28 | 2016-09-07 | Advanced Circulatory Systems Inc. | Ventilator and methods for treating head trauma and low blood circulation |
| AU2006345361B2 (en) | 2006-05-29 | 2014-04-10 | Hibernation Therapeutics, A Kf Llc | Improved tissue maintenance |
| CA2692256C (en) | 2006-07-25 | 2017-01-10 | Hibernation Therapeutics Limited | Trauma therapy |
| US7717855B2 (en) | 2006-12-06 | 2010-05-18 | The Hospital For Sick Children | System for performing remote ischemic preconditioning |
| EP2173353B1 (en) | 2007-03-02 | 2015-05-06 | Hibernation Therapeutics, a KF LLC | Composition including Adenosine and Lignocaine |
| US20110046039A1 (en) * | 2007-03-09 | 2011-02-24 | George Mason Intellectual Properties Inc. | Post-exposure prophylaxis and treatment of infections |
| US9352111B2 (en) | 2007-04-19 | 2016-05-31 | Advanced Circulatory Systems, Inc. | Systems and methods to increase survival with favorable neurological function after cardiac arrest |
| US8151790B2 (en) | 2007-04-19 | 2012-04-10 | Advanced Circulatory Systems, Inc. | Volume exchanger valve system and method to increase circulation during CPR |
| SG185322A1 (en) * | 2007-07-25 | 2012-11-29 | Hibernation Therapeutics Ltd | Improved organ protection, preservation and recovery |
| US20110190727A1 (en) * | 2010-02-02 | 2011-08-04 | Boston Scientific Scimed, Inc. | Intervascular catheter, system and method |
| US9724266B2 (en) | 2010-02-12 | 2017-08-08 | Zoll Medical Corporation | Enhanced guided active compression decompression cardiopulmonary resuscitation systems and methods |
| US12016820B2 (en) | 2010-02-12 | 2024-06-25 | Zoll Medical Corporation | Enhanced guided active compression decompression cardiopulmonary resuscitation systems and methods |
| US20120330199A1 (en) * | 2010-07-02 | 2012-12-27 | ResQSystems, Inc. | Methods and systems for reperfusion injury protection after cardiac arrest |
| KR20130040878A (ko) | 2010-04-08 | 2013-04-24 | 더 호스피탈 포 식 칠드런 | 외상성 손상을 위한 원격 허혈 처치의 사용 |
| US8708996B2 (en) | 2010-04-30 | 2014-04-29 | Abbott Cardiovascular Systems, Inc. | Methods and device for synergistic mitigation of reperfusion injury after an ischemic event |
| US8480650B2 (en) | 2010-04-30 | 2013-07-09 | Abbott Cardiovascular Systems Inc. | Method for increased uptake of beneficial agent and ejection fraction by postconditioning procedures |
| US8540669B2 (en) | 2010-04-30 | 2013-09-24 | Abbott Cardiovascular Systems Inc. | Catheter system providing step reduction for postconditioning |
| US9168361B2 (en) | 2010-04-30 | 2015-10-27 | Abbott Cardiovascular Systems Inc. | Balloon catheter exhibiting rapid inflation and deflation |
| US8821438B2 (en) | 2010-04-30 | 2014-09-02 | Abbott Cardiovascular Systems, Inc. | Catheter system having a fluid circuit |
| EP2563446A1 (en) | 2010-04-30 | 2013-03-06 | Abbott Cardiovascular Systems Inc. | Improved balloon catheter exhibiting rapid inflation and deflation |
| US9533124B2 (en) | 2011-04-14 | 2017-01-03 | Abbott Cardiovascular Systems Inc. | Reperfusion injury devices |
| BR112014012054A2 (pt) * | 2011-11-18 | 2017-05-30 | Apotex Tech Inc | métodos de tratamento com deferiprona |
| JP2015500733A (ja) | 2011-12-19 | 2015-01-08 | レスキューシステムズ インコーポレイテッドＲｅｓｑｓｙｓｔｅｍｓ，Ｉｎｃ． | 治療のための胸腔内圧調節システムおよび方法 |
| JP2016512709A (ja) | 2013-03-15 | 2016-05-09 | ザ・ホスピタル・フォー・シック・チルドレンＴｈｅ Ｈｏｓｐｉｔａｌ Ｆｏｒ Ｓｉｃｋ Ｃｈｉｌｄｒｅｎ | 遠隔虚血コンディショニングを用いてオートファジをモジュレートする方法 |
| WO2014199239A2 (en) | 2013-03-15 | 2014-12-18 | The Hospital For Sick Children | Methods relating to the use of remote ischemic conditioning |
| CA2904504A1 (en) | 2013-03-15 | 2014-09-18 | The Hospital For Sick Children | Treatment of erectile dysfunction using remote ischemic conditioning |
| US9811634B2 (en) | 2013-04-25 | 2017-11-07 | Zoll Medical Corporation | Systems and methods to predict the chances of neurologically intact survival while performing CPR |
| US20140358047A1 (en) | 2013-05-30 | 2014-12-04 | ResQSystems, Inc. | End-tidal carbon dioxide and amplitude spectral area as non-invasive markers of coronary perfusion pressure and arterial pressure |
| BR112016000809A2 (pt) | 2013-07-17 | 2017-08-22 | Hibernation Therapeuitics A Kf Llc | Método para tratar infecção, sepsia e lesão |
| US10265495B2 (en) | 2013-11-22 | 2019-04-23 | Zoll Medical Corporation | Pressure actuated valve systems and methods |
| US10092591B2 (en) * | 2014-02-27 | 2018-10-09 | University Of Alaska Fairbanks | Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia |
| WO2019140073A1 (en) * | 2018-01-10 | 2019-07-18 | Tufts Medical Center, Inc. | Systems and methods for left ventricular unloading in treating myocardial infarction |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4781677A (en) * | 1985-07-17 | 1988-11-01 | Wilcox Gilbert M | Method of treatment utilizing a double balloon nasobiliary occlusion catheter |
| US4691708A (en) * | 1986-03-10 | 1987-09-08 | Cordis Corporation | Optical pressure sensor for measuring blood pressure |
| US4769010A (en) * | 1987-02-11 | 1988-09-06 | Strato Medical Corporation | Catheter needle assembly with adjustable height support |
| US4901731A (en) * | 1988-04-27 | 1990-02-20 | Millar Instruments, Inc. | Single sensor pressure differential device |
| US4929236A (en) * | 1988-05-26 | 1990-05-29 | Shiley Infusaid, Inc. | Snap-lock fitting catheter for an implantable device |
| US5011469A (en) * | 1988-08-29 | 1991-04-30 | Shiley, Inc. | Peripheral cardiopulmonary bypass and coronary reperfusion system |
| US4943277A (en) * | 1989-03-24 | 1990-07-24 | Bolling Steven F | Retrograde coronary sinus cardioplegia cannula and method for using same in heart surgery |
| US5129891A (en) * | 1989-05-19 | 1992-07-14 | Strato Medical Corporation | Catheter attachment device |
| DE4003425A1 (de) * | 1990-02-06 | 1991-08-08 | Beyersdorf Friedhelm Dr Med | Reperfusionsvorrichtung |
| US5108369A (en) * | 1990-03-15 | 1992-04-28 | Diagnostic Devices Group, Limited | Dual-diameter multifunction catheter |
| US5190520A (en) * | 1990-10-10 | 1993-03-02 | Strato Medical Corporation | Reinforced multiple lumen catheter |
| US5178612A (en) * | 1990-10-10 | 1993-01-12 | Strato Medical Corporation | Compressible split cylinder bayonet locking device for attachment of a catheter to a fluid transfer device |
| US5156600A (en) * | 1990-10-10 | 1992-10-20 | Strato Medical Corporation | Bidirectional check valve catheter |
| US6309639B1 (en) * | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
| US5112301A (en) * | 1991-06-19 | 1992-05-12 | Strato Medical Corporation | Bidirectional check valve catheter |
| US5584803A (en) * | 1991-07-16 | 1996-12-17 | Heartport, Inc. | System for cardiac procedures |
| US5879499A (en) * | 1996-06-17 | 1999-03-09 | Heartport, Inc. | Method of manufacture of a multi-lumen catheter |
| US5769812A (en) * | 1991-07-16 | 1998-06-23 | Heartport, Inc. | System for cardiac procedures |
| US5195942A (en) * | 1991-08-12 | 1993-03-23 | Institute Of Critical Care Medicine | Cardiac arrest treatment |
| US6224619B1 (en) * | 1991-12-17 | 2001-05-01 | Heartport, Inc. | Blood vessel occlusion trocar having size and shape varying insertion body |
| US5224938A (en) * | 1992-03-18 | 1993-07-06 | Strato Medical Corporation | Valved catheter |
| US6283127B1 (en) * | 1992-12-03 | 2001-09-04 | Wesley D. Sterman | Devices and methods for intracardiac procedures |
| US6325067B1 (en) * | 1992-12-03 | 2001-12-04 | Wesley D. Sterman | Methods and systems for performing thoracoscopic coronary bypass and other procedures |
| US5573502A (en) * | 1993-05-26 | 1996-11-12 | Quest Medical, Inc. | Display panel and controls for blood mixture delivery system |
| US5702880A (en) * | 1993-06-04 | 1997-12-30 | Biotime, Inc. | Blood substitute comprising 0-5 mM K+ |
| US5759170A (en) * | 1993-11-30 | 1998-06-02 | Heartport, Inc. | Method for intraluminally inducing cardioplegic arrest and catheter for use therein |
| US5478309A (en) * | 1994-05-27 | 1995-12-26 | William P. Sweezer, Jr. | Catheter system and method for providing cardiopulmonary bypass pump support during heart surgery |
| US5695457A (en) * | 1994-07-28 | 1997-12-09 | Heartport, Inc. | Cardioplegia catheter system |
| US6607698B1 (en) * | 1997-08-15 | 2003-08-19 | Therox, Inc. | Method for generalized extracorporeal support |
| US5868776A (en) * | 1996-09-03 | 1999-02-09 | Ideas For Medicine, Inc. | Overlay dual balloon catheter and method for use thereof |
| US5993382A (en) * | 1996-11-27 | 1999-11-30 | Horizon Medical Products, Inc. | Lighted catheter device and method for use and manufacture thereof |
| US5957879A (en) * | 1997-01-24 | 1999-09-28 | Heartport, Inc. | Methods and devices for maintaining cardiopulmonary bypass and arresting a patient's heart |
| DE19702402A1 (de) * | 1997-01-24 | 1998-07-30 | Beyersdorf Friedhelm Univ Prof | Verfahren und Reperfusionsvorrichtung |
| US5755687A (en) * | 1997-04-01 | 1998-05-26 | Heartport, Inc. | Methods and devices for occluding a patient's ascending aorta |
| DE19741635A1 (de) * | 1997-09-22 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| US6991645B2 (en) * | 1998-01-23 | 2006-01-31 | Innercool Therapies, Inc. | Patient temperature regulation method and apparatus |
| US6295990B1 (en) * | 1998-02-03 | 2001-10-02 | Salient Interventional Systems, Inc. | Methods and systems for treating ischemia |
| US6736790B2 (en) * | 1998-02-25 | 2004-05-18 | Denise R. Barbut | Method and system for selective or isolated integrate cerebral perfusion and cooling |
| US6235714B1 (en) * | 1998-03-23 | 2001-05-22 | Sudhir Paul | Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| US6602467B1 (en) * | 1998-07-24 | 2003-08-05 | Therox, Inc. | Apparatus and method for blood oxygenation |
| US6830581B2 (en) * | 1999-02-09 | 2004-12-14 | Innercool Therspies, Inc. | Method and device for patient temperature control employing optimized rewarming |
| US7914564B2 (en) * | 1999-02-09 | 2011-03-29 | Innercool Therapies, Inc. | System and method for patient temperature control employing temperature projection algorithm |
| US6315768B1 (en) * | 1999-06-08 | 2001-11-13 | Richard K. Wallace | Perfusion procedure and apparatus for preventing necrosis following failed balloon angioplasty |
| US6576191B1 (en) * | 1999-09-30 | 2003-06-10 | Therox, Inc. | Apparatus for blood oxygenation |
| US6387324B1 (en) * | 1999-09-30 | 2002-05-14 | Therox, Inc. | Apparatus and method for blood oxygenation |
| US6462066B2 (en) * | 1999-12-02 | 2002-10-08 | University Of South Florida | Method and composition for treatment of ischemic neuronal reperfusion injury |
| US20030040531A1 (en) * | 2000-01-25 | 2003-02-27 | Kazuyuki Fujishima | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist |
| US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| US6900178B2 (en) * | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
| US6645938B2 (en) * | 2000-10-10 | 2003-11-11 | Zymogenetics, Inc. | Protection against ischemia and reperfusion injury |
| US6585675B1 (en) * | 2000-11-02 | 2003-07-01 | Chf Solutions, Inc. | Method and apparatus for blood withdrawal and infusion using a pressure controller |
| US6423705B1 (en) * | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| US20030216582A1 (en) * | 2001-02-08 | 2003-11-20 | Nicholas Nikolaides | 2-carboxamide-benzimidazoles useful in the treatment and prevention of ischemic reperfusion injury |
| WO2002092124A1 (en) * | 2001-05-11 | 2002-11-21 | Wyeth | Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof |
| US20040131607A1 (en) * | 2001-06-08 | 2004-07-08 | Carroll Michael C. | Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury |
| AU2002322520A1 (en) * | 2001-07-17 | 2003-03-03 | Kerberos Proximal Solutions | Fluid exchange system for controlled and localized irrigation and aspiration |
| JP2003096308A (ja) * | 2001-09-25 | 2003-04-03 | Asahi Glass Co Ltd | 撥水撥油性組成物およびその造形品 |
| WO2003041640A2 (en) * | 2001-11-09 | 2003-05-22 | The General Hospital Corporation | METHODS FOR TREATING ISCHEMIC REPERFUSION INJURY USING IkB KINASE-BETA INHIBITORS |
| US6544950B1 (en) * | 2001-12-06 | 2003-04-08 | University Of Kentucky Research Foundation | Seventeen amino acid peptide (Peptide P) for treating ischemia and reperfusion injury |
| AU2002364231A1 (en) * | 2001-12-21 | 2003-07-30 | Emory University | Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs |
| US6844361B2 (en) * | 2002-02-04 | 2005-01-18 | Aventis Pharma Deutschland Gmbh | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor |
| US20030220383A1 (en) * | 2002-02-14 | 2003-11-27 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders |
| EA200500005A1 (ru) * | 2002-06-12 | 2005-06-30 | Байоджен Айдек Ма Инк. | Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина |
| EP1523310A2 (en) * | 2002-07-09 | 2005-04-20 | The Scripps Research Institute | Method to inhibit ischemia and reperfusion injury |
| EP2392562B1 (en) * | 2002-07-29 | 2018-03-07 | Cardax Pharma, Inc. | Structural carotenoid analogs for the inhibition and amelioration of disease |
| US20050143475A1 (en) * | 2002-07-29 | 2005-06-30 | Lockwood Samuel F. | Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
| US20040111079A1 (en) * | 2002-12-03 | 2004-06-10 | Richard Hayes | Targeted sanguinous drug solution delivery to a targeted organ |
| US7004961B2 (en) * | 2003-01-09 | 2006-02-28 | Edward Wong | Medical device and method for temperature control and treatment of the brain and spinal cord |
| AU2004216176B2 (en) * | 2003-02-21 | 2008-04-03 | Genentech, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| WO2004084933A1 (en) * | 2003-03-28 | 2004-10-07 | Faron Pharmaceuticals Oy | Elevation of adenosine level by cytokine-induced expression of cd73 |
| US20060051407A1 (en) * | 2003-06-27 | 2006-03-09 | Yoram Richter | Method of treating ischemia-reperfusion injury |
| US20050187221A1 (en) * | 2003-09-08 | 2005-08-25 | Japan Tobacco Inc. | Method of treating ischemia reperfusion injury |
| US20060029589A1 (en) * | 2004-06-01 | 2006-02-09 | Hartmut Weiler | Induction of heterozygous FV Leiden carrier status to reduce mortality in sepsis and to prevent organ damage caused by inflammation and/or ischemia-reperfusion injury |
| US7304073B2 (en) * | 2004-08-20 | 2007-12-04 | Wyeth | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors |
| US20060136023A1 (en) * | 2004-08-26 | 2006-06-22 | Dobak John D Iii | Method and apparatus for patient temperature control employing administration of anti-shivering agents |
| US7332159B2 (en) * | 2004-09-30 | 2008-02-19 | Board Of Regents Of The University Of Nebraska | Method and composition for inhibiting reperfusion injury in the brain |
-
2005
- 2005-12-20 JP JP2007548436A patent/JP2008525468A/ja not_active Withdrawn
- 2005-12-20 WO PCT/US2005/046417 patent/WO2006069170A2/en not_active Ceased
- 2005-12-20 EP EP05855042A patent/EP1827298A4/en not_active Withdrawn
- 2005-12-20 AU AU2005319144A patent/AU2005319144A1/en not_active Abandoned
- 2005-12-20 CA CA002592142A patent/CA2592142A1/en not_active Abandoned
- 2005-12-20 US US11/793,508 patent/US20080097385A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013510832A (ja) * | 2009-11-16 | 2013-03-28 | アンスティテュ ナシオナル ドゥ ラ ルシェルシュ アグロノミック | Ａ型インフルエンザウイルス感染症の治療または予防用のｐａｒ−１アンタゴニスト |
| JP2013523240A (ja) * | 2010-03-31 | 2013-06-17 | ザ・ホスピタル・フォー・シック・チルドレン | 心筋梗塞後の結果を改善するための遠隔虚血コンディショニングの使用 |
| JP2016052600A (ja) * | 2010-03-31 | 2016-04-14 | ザ・ホスピタル・フォー・シック・チルドレンＴｈｅ Ｈｏｓｐｉｔａｌ Ｆｏｒ Ｓｉｃｋ Ｃｈｉｌｄｒｅｎ | 心筋梗塞後の結果を改善するための遠隔虚血コンディショニングの使用 |
| JP2012210361A (ja) * | 2011-03-31 | 2012-11-01 | Terumo Corp | 肢部圧迫装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1827298A2 (en) | 2007-09-05 |
| WO2006069170A3 (en) | 2007-01-04 |
| AU2005319144A1 (en) | 2006-06-29 |
| CA2592142A1 (en) | 2006-06-29 |
| US20080097385A1 (en) | 2008-04-24 |
| WO2006069170A2 (en) | 2006-06-29 |
| EP1827298A4 (en) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525468A (ja) | ポストコンディショニング臓器保護作用を増強する治療補助薬 | |
| JP4514838B2 (ja) | 過増殖性の血管疾患を予防するための医薬組成物 | |
| US5453436A (en) | Treatment of athereosclerosis using, carbazolyl-(4)-oxypropanolamine compounds | |
| JP2009172394A (ja) | 心臓および他の器官における虚血−再灌流傷害の軽減のための事後調節 | |
| EP4114466B1 (en) | Treatment of pain and vasoconstriction | |
| EP1258250B1 (en) | Nerve protective drugs | |
| ES2349244T3 (es) | Procedimientos para reducir la angiogénesis. | |
| Colson et al. | Mechanisms of renal hemodynamic impairment during infrarenal aortic cross-clamping | |
| Velasco et al. | Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine | |
| US20240252457A1 (en) | Treatment or Prevention of Ischaemia Reperfusion Injury | |
| Scriabine et al. | Nimodipine: Pharmacological and clinical results in cerebral ischemia | |
| Rahn | How should we treat a hypertensive emergency? | |
| EP1190714A2 (en) | Method for the treatment of thromboembolic disorders in patients with aspirin resistance | |
| Kenyon | New Drug Approvals: Clevidipine: An Ultra Short-Acting Calcium Channel Antagonist for Acute Hypertension | |
| KR20190072011A (ko) | 나토키나제와 항염증제를 유효성분으로 포함하는 혈소판 응집 억제용 또는 혈전용해용 의약 조성물 | |
| EP3771467A1 (en) | Ss-31 for the prevention and/or treatment of aneurysm | |
| Kawabata et al. | Experience with calcium antagonists nitrendipine, diltiazem, and verapamil and β2‐agonist salbutamol in salvaging ischemic skin flaps in rabbits | |
| EP3085371A1 (en) | Parthenolide and its derivatives for use in the treatment of axonal damage | |
| EP2091521A1 (en) | Anticonvulsive pharmaceutical compositions | |
| EP2968319A1 (en) | Treatment for chemotherapy-induced cognitive impairment | |
| HUT76834A (en) | Use of (s)-adenosyl-l-methionine (same) and its physiologically compatible salts for preparing pharmaceutical compositions for treating reperfusion damage triggered by temporary focal ischemia | |
| KR20080033238A (ko) | 재관류 손상을 치료하기 위한 가용성 구아닐레이트시클라제의 활성자의 용도 | |
| JP5011496B2 (ja) | 脳梗塞抑制剤 | |
| EP1582213A1 (en) | Use of adenosine for treating surgery related ischemia | |
| WO2025257421A1 (en) | Combinations of mek and pkc inhibitors for treating stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081205 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081205 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110817 |